Braveheart Bio Strengthens Clinical Leadership as It Prepares Global Pivotal oHCM Trial

New updates have been reported about Braveheart Bio.

Braveheart Bio has appointed Emil deGoma, M.D., as Chief Medical Officer, a move aimed at bolstering clinical leadership as the company advances its lead asset BHB-1893 toward a planned global pivotal trial in obstructive hypertrophic cardiomyopathy in 2026. DeGoma will oversee clinical strategy, medical affairs, and external medical engagement, positioning the company to execute late-stage development in a complex cardiovascular indication with significant unmet need.

Chief Executive Officer and President Travis Murdoch, M.D., said deGoma’s blend of academic cardiology and industry experience is intended to support BHB-1893 as a potential new standard of care in hypertrophic cardiomyopathy and related conditions. DeGoma previously led medical research at Tourmaline Bio and managed large cardiovascular outcomes programs at Akebia Therapeutics, experience that Braveheart Bio expects to leverage as it designs and runs global trials backed by investors including Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences.

DeGoma, who trained at Harvard and Stanford and is a Fellow of both the American College of Cardiology and the American Heart Association, emphasized the scale of unmet need in hypertrophic cardiomyopathy and described BHB-1893 as a potentially best-in-class therapy. For executives and stakeholders, the appointment signals that Braveheart is transitioning from early clinical development to pivotal-stage execution, with organizational focus on regulatory-grade data generation, global trial infrastructure, and deeper engagement with key opinion leaders in cardiovascular medicine.

As Braveheart Bio moves toward its 2026 pivotal trial start, the strengthened medical leadership is likely to influence trial design, patient selection, and regulatory strategy, all of which will be critical to future valuation and potential partnering or commercialization options. The company remains focused on progressing BHB-1893 through late-stage clinical development with the explicit goal of changing the treatment paradigm in obstructive hypertrophic cardiomyopathy and adjacent cardiovascular indications.